28th University of Chicago Comprehensive Cancer Center Developmental Therapeutics Symposium

28th University of Chicago Comprehensive Cancer Center Developmental Therapeutics Symposiu is organized by Meeting Achievements, LLC, The University of Chicago - Center for Continuing Medical Education and will be held on May 02, 2025 at David Rubenstein Forum at the University of Chicago, Chicago, Illinois, United States of America.

Description:
 Participants at this unique forum will critically analyze data from important clinical studies, engage in thought-provoking discussions on cutting-edge investigational agents in active trials, and delve into the scientific rationale and results of studies featuring novel cancer treatments. Gain actionable insights to seamlessly integrate these innovative therapies into your clinical practice, contribute to the development and success of impactful trials, and strengthen your role as a leader in the oncology community. This activity will empower you with the latest knowledge and tools to effectively implement precision medicine in cancer care, driving improved outcomes for your patients.

Learning Objectives:
After this activity, participants will be able to:

• Recall new approaches to pre- and post-FDA approval for dosing and scheduling of anti-cancer agents;
• Recognize the therapeutic ratio of novel agents and approaches to define dose reductions that maintain efficacy;
• State the clinical effects of novel immunotherapeutic agents, including novel checkpoint inhibitors, bispecific antibodies, and novel cellular therapies;
• Identify how to assess patient suitability for participation in ongoing and upcoming cancer clinical trials and projects;
• Cite the relevant pharmacologic and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches, including novel PET tracer imaging and circulating tumor DNA assays;
• Describe advances in the use of systemic therapies for cancer, including those targeting specific molecular alterations such as DNA repair mutations, specific chromosomal translocations, and tyrosine kinase mutations;
• Assess the status of and developmental pathway for antibody-drug conjugates in solid and hematologic tumors.